ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

March 21, 2006 11:42 ET

ALDA Pharmaceuticals Files 20F with SEC

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 21, 2006) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") is pleased to announce that it has completed the filing of its initial 20F registration statement on the SEC's EDGAR system. The 20F, subject to SEC review, provides ALDA with US registration and a wider potential investor base as a company registered under the Securities Act of 1934. The company's documents can be viewed at www.sec.gov by typing "ALDA Pharmaceuticals" into the "Search" box.

About ALDA Pharmaceuticals

ALDA has developed and markets wide spectrum, non-toxic, non-corrosive, biodegradable infection control products based on its patent-pending T36® technology. Its lead product, T36® Disinfectant, is acknowledged to be effective against all bacteria and viruses including Avian Flu, SARS, Norwalk Virus, HIV, Legionella and Hepatitis because of its ability to kill polio and TB.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.


The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information